Diopsys, Inc. has settled all claims with the Department of Justice related to its Nova ERG device marketing activities from the period of 2015-2021. The settlement provides for a series of guaranteed payments totaling $1,225,000 and contingent payments up to a maximum of $13,025,000 to be made over a period of 6 years.

“We take regulatory requirements seriously and this agreement reinforces that commitment,” stated Michael Egleston, CFO, Diopsys, Inc. “With the settlement now complete, Diopsys can proceed with submitting a new 510K application to the FDA for its redesigned ERG device and working to restore its ERG presence in the US marketplace.”

About Diopsys, Inc.

Diopsys, Inc. is a medical device company commercializing the NOVA™ Vision Testing System. NOVA is a comprehensive electrophysiology platform that provides objective assessment of the entire pathway for visual and neuro-visual disorders. VEP is available in the USA and select countries outside of the USA. ERG is only available outside of the USA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250328460541/en/